|
Please Note:
Enrolment is closed. This study is no
longer recruiting participants |
The
purpose of this study is to determine the
safety, effectiveness,
and recommended dose of Proxinium™ in North
American patients with Squamous Cell Head
and Neck Cancer
| Condition
|
Intervention |
Phase |
- Recurrent Squamous Cell Carcinoma
of the Head and Neck
- Carcinoma, Squamous Cell
- Neoplasms, Squamous Cell
- Head and Neck Neoplasms
- Mouth Neoplasms
- Head and Neck Cancer
|
Drug: Proxinium |
Phase II |
Study
Type:
Interventional
Study Design:
Treatment, Non-Randomized, Open Label, Uncontrolled,
Single Group Assignment, Safety/Efficacy Study
Official
Title:
A
Phase II, Open-Label Study to Evaluate the
Safety, Tolerability, and Pharmacokinetic
Profile of Proxinium™ in Patients With
Advanced Squamous Cell Carcinoma of the
Head and Neck Who Have Received at Least One
Anti-Cancer Treatment Regimen for
Advanced Disease
|
